1-(3-methyl-butoxy)-pentane | 92097-07-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-methyl-butoxy)-pentane
• 英文别名: isopentyl-pentyl ether；Isopentyl-pentyl-aether；Iso-pentoxypentane；1-(3-methylbutoxy)pentane
• CAS: 92097-07-9
• 化学式: C₁₀H₂₂O
• 分子量: 158.284
• InChiKey: MCUJGFHMEIYUJO-UHFFFAOYSA-N

物化性质

• 沸点：
  160 °C
• 密度：
  0.7824 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-methyl-butoxy)-pentane 在 三溴化磷 作用下， 以 吡啶 为溶剂， 生成 1-bromo-5-(3-methyl-butoxy)-pentane
  参考文献：
  名称：

  DE2319573

  摘要：

  公开号：
• 作为产物：
  描述：

  异戊醇钠 在 乙醚 、 异戊醇 、 镍 作用下， 生成 1-(3-methyl-butoxy)-pentane
  参考文献：
  名称：

  Gol'dfarb; Konstantinow, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1957, p. 217,219; engl. Ausg. S. 229, 231

  摘要：

  DOI：

文献信息

• [EN] NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS<br/>[FR] NOUVEAUX GLYCOPEPTIDES SEMI-SYNTHÉTIQUES COMME AGENTS ANTIBACTÉRIENS
  申请人：LEAD THERAPEUTICS INC

  公开号：WO2010065174A1

  公开（公告）日：2010-06-10

  Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi¬ synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

  本文介绍了具有抗菌活性的半合成糖肽，特别是在这里描述的半合成糖肽是通过化学修饰糖肽（化合物A、化合物B、化合物H或化合物C）或通过在酸性介质中水解母体糖肽的氨基酸-4的二糖基团，从而得到氨基酸-4单糖的方法制备的；将单糖转化为氨基糖衍生物；用特定的酰基基团对这些支架上氨基酸-4氨基取代糖基团上的氨基取代基进行酰化；并将这些支架上的大环环上的酸基团转化为某些取代酰胺。关键反应是用异氰酸酯处理适当保护的中间化合物。还提供了合成这些化合物的方法，含有这些化合物的制药组合物以及用于治疗和/或预防疾病，特别是细菌感染的化合物的使用方法。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。
• Compounds exhibiting thrombopoietin receptor agonism
  申请人：Takayama Masami

  公开号：US20070043087A1

  公开（公告）日：2007-02-22

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  化合物的一般式(I)表示的复合物，其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。这是一个前药、药物可接受的盐或其溶剂。
• 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0232776A2

  公开（公告）日：1987-08-19

  Disclosed herein are novel prostaglandin I2 (PGI2) derivatives exhibiting excellent in vivo duration and acitivities, said derivatives being represented by the general formula: wherein R1, X, R2 and R3 are as defined herein.

  本文公开了新型前列腺素 I2 (PGI2) 衍生物，其在体内的持续时间和活性极佳，所述衍生物由通式表示： 其中 R1、X、R2 和 R3 如本文所定义。
• 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0365678A1

  公开（公告）日：1990-05-02

  2,5,6,7-Tetranor-4,8-inter-m-phenylene PGl2 derivatives such as 16-methyl-2,5,6,-tetranor-4,8-!nter-m-phenylene PGl2 and its methyl ester, 17-methyl-2,5,6,7-tetranor-4,8-inter-m-phenylene PGl2 and its methyl ester, 15-phenyl-2,5,6,7,16,17,18,19,20-nonanor-4,8-inter-m-phenylene PGI2, 16-methyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-l-nter-m- phenylene PGl2, 16,16-dimethyl-17-phenyl-2,5,6,7,18,19,20-heptanor--4,8-inter-m-phenylene PG12, 16-methyl-16-phenoxy-2.5,6,7,17,18,19,20-octanor-4, 8- ,inter-m-phenylene PGI2, 16-methyl-16-phenoxy-2,5,6,7,18,19,20-heptanor-4,8--inter-m- phenylene PGl2 and its methyl ester and 3-decarboxy-3-hydroxymethyl-16-methyl-16-phenoxy-2,5.6.7,18,19,20-heptanor- 4,8-inter-m-phenylene PG12, useful as medicines, are disclosed. These derivatives are useful as, for example, antiulceric agents, hypotensives, and antithrombotic agents.

  nter-m-phenylene PGl2 及其甲酯、17-甲基-2,5,6,7-tetranor-4,8-inter-m-phenylene PGl2 及其甲酯、15-苯基-2,5,6,7,16,17,18,19,20-nonanor-4,8-inter-m-phenylene PGI2、16-methyl-17-phenyl-2,5,6,7,18,19,20-heptanor-4,8-l-nter-m- phenylene PGl2, 16,16-dimethyl-17-phenyl-2,5,6,7,18,19,20-heptanor--4,8-inter-m-phenylene PG12, 16-methyl-16-phenoxy-2.5,6,7,17,18,19,20-辛硼烷-4,8-间亚苯基 PGI2、16-甲基-16-苯氧基-2,5,6,7,18,19,20-庚硼烷-4,8-间亚苯基 PGl2 及其甲酯和 3-癸羧基-3-羟甲基-16-甲基-16-苯氧基-2,5,6,7,18,19,20-庚硼烷-4,8-间亚苯基 PGl2 及其甲酯。6.7,18,19,20-heptanor- 4,8-inter-m-phenylene PG12，可用作药物。这些衍生物可用作抗溃疡剂、降血压剂和抗血栓剂等。